MedTrace Logo

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

NCT01300260 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-10-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

LY2189265

Administered subcutaneously

DRUG

Placebo

Administered subcutaneously

DRUG

Insulin

Administered intravenously

DRUG

Glucose

Administered intravenously

DRUG

Glucagon

Administered intravenously

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300260 on ClinicalTrials.gov